Zenklusen, Isabelle http://orcid.org/0000-0002-8106-8087
Hsin, Chih-Hsuan
Schilling, Uta
Kankam, Martin
Krause, Andreas
Ufer, Mike
Dingemanse, Jasper
Clinical trials referenced in this document:
Documents that mention this clinical trial
Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects
https://doi.org/10.1007/s40262-021-01097-9
Article History
Accepted: 21 November 2021
First Online: 28 December 2021
Declarations
:
: The study was funded by Idorsia Pharmaceuticals Ltd.
: During the conduct of this study, IZ, CH, US, AK, MU, and JD were full-time employees of Idorsia Pharmaceuticals Ltd and MK was the principal investigator.
: The protocol was approved by the Midlands Independent Review Board, USA. This study was performed according to Good Clinical Practice and in accordance with the principles of the Declaration of Helsinki.
: All participants provided written informed consent prior to the initiation of study-related procedures.
: Not applicable (no personal data were reported).
: Datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: The model codes are available upon request.
: IZ wrote the manuscript, CH and AK conducted the PK/PD modeling, US, MU, and JD designed and analyzed the study, and MK was the principal investigator of the study. All authors revised the manuscript critically for important intellectual content and approved the version to be submitted.